BCL2L11 and cancer: Mesothelin (MSLN) overexpression in PDAC promotes cancer progression and aggressiveness by various regulating various molecular events including, the elevation of Cyclin E levels via STAT3 activation, inhibition of pro-apoptotic proteins (Bim & Bax), induction of anti-apoptotic proteins (Bcl-2 & Bcl-xl) respectively [59, 60].